Business
Rocket Pharmaceuticals Announces Buildout of R&D and Manufacturing Facility to Support Development of Innovative Gene Therapy Pipeline
—New 103,720 ft2 Facility to Serve as Headquarters and House 150 Employees in Cranbury, NJ— —State of the Art R&D Facility to Support Manufacturing Including
About this update from Rocket Pharmaceuticals, Inc.
[{"type":"text","content":"\n—New 103,720 ft2 Facility to Serve as Headquarters and House 150 Employees in Cranbury, NJ—\n\n—State of the Art R&D Facility to Support Manufacturing Including AAV Drug Product—\n\n—cGMP Production to be Initiated in 2021 for Planned Phase 2 Study of First AAV-based Gene Therapy, RP-A501 for the Treatment of Danon Disease—\n\n CRANBURY, N.J.--(BUSINESS WIRE)--\nRocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces the Company’s plans for the buildout of its new Research and Development (R&D) and Chemistry, Manufacturing and Controls (CMC) operation which will also serve as the Company’s new headquarters in Cranbury, New Jersey. This new 103,720 ft2 facility will support clinical development of Rocket’s growing pipeline of lentivirus (LV) and adeno-associated virus (AAV) gene therapies from discovery through pivotal trials, with space for potential future expansion and commercialization. This buildout comes on the heels of the Company’s recent successful capital raise of approximately $300 million that provides a cash runway into the second half of 2023.\nThis press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210111005331/en/Rocket Pharmaceuticals Headquarters (Photo: Business Wire)\n“Investing in R&D and manufacturing innovation, talent, and capacity through this new world-class facility will allow us to deliver on our mission of bringing five curative gene therapies to rare disease patients by 2025,” said Gaurav Shah, M.D., President and Chief Executive Officer of Rocket. “With data on five clinical programs expected this year, including two that are in registration-enabling trials, these new capabilities will enable us to work with continued urgency and purpose towards bringing transformational therapies to patients.”\n\n“We are collaborating with some of the best scientists and innovators worldwide. This new facility is instrumental in bolstering Rocket’s gene therapy capabilities to rapidly advance multiple platforms and programs efficiently and effectively. Producing clinical drug product will enable greater control of supply, cost, quality, and timing to pave a smoother path toward commercialization,” added Kinnari Patel, Pharm.D., MBA, ...